Biocure Technology Inc.
CUREX
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -80.20% | -76.13% | -70.32% | 55.99% | 60.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.20% | -76.13% | -70.32% | 55.99% | 60.94% |
| Operating Income | 80.20% | 76.13% | 70.32% | -55.99% | -60.94% |
| Income Before Tax | 94.20% | 82.99% | 82.45% | -263.78% | -268.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 94.20% | 82.99% | 82.45% | -263.78% | -268.24% |
| Earnings from Discontinued Operations | -- | -- | -- | 95.70% | 96.53% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -91.86% | -94.70% |
| Net Income | 94.24% | 84.00% | 85.61% | -346.70% | -385.29% |
| EBIT | 80.20% | 76.13% | 70.32% | -55.99% | -60.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 95.73% | 90.94% | 91.09% | -392.28% | -428.88% |
| Normalized Basic EPS | 82.09% | 83.18% | 82.08% | -84.40% | -118.97% |
| EPS Diluted | 95.73% | 90.94% | 91.09% | -392.28% | -428.88% |
| Normalized Diluted EPS | 82.09% | 83.18% | 82.08% | -84.40% | -118.97% |
| Average Basic Shares Outstanding | 10.19% | 4.22% | 0.14% | -13.82% | -14.91% |
| Average Diluted Shares Outstanding | 10.19% | 4.22% | 0.14% | -13.82% | -14.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |